Findacure

November 19, 2015

Findacure has teamed up with the US-based Cures Within Reach to help develop the concept of social investment for rediscovery research for fundamental diseases. Dr Bruce Bloom of Cures Within Reach explains how this works:

Rediscovery research improves lives by taking drugs approved for one disease and repurposing them to create a new treatment in a different disease. When the repurposed drug is generic and able to be taken in the current dosage and formulation, there is often little or no profit to be gained, so industry does not fund these repurposing projects. Currently, philanthropy funds them, and that funding is hard to get.

Science Translational Medicine, via PRNewswire

November 12, 2015

Researchers have taken a significant step forward in developing gene therapy against a fatal neurodegenerative disease that strikes children. By delivering a working version of a gene to produce a key enzyme that is lacking in Batten disease, the scientists delayed symptoms and extended lifespan in dogs with a comparable disease.

Nature Reviews Clinical Oncology, October 20, 2015

Francesco Bertolini, Vikas P. Sukhatme & Gauthier Bouche

In most countries, healthcare service budgets are not likely to support the current explosion in the cost of new oncology drugs. Repurposing the large arsenal of approved, non-anticancer drugs is an attractive strategy to offer more-effective options to patients with cancer, and has the substantial advantages of cheaper, faster and safer preclinical and clinical validation protocols. The potential benefits are so relevant that funding of academically and/or independently driven preclinical and clinical research programmes should be considered at both national and international levels.

Pharmaceutical Technology, Volume 39 Issue 17

August 6, 2015

A. Shanley

Outsourcing opportunity?


PharmTech: What role do contract research organizations (CROs) and contract manufacturing organizations (CMOs) play in drug repurposing? Are there any new business models that you are seeing in CMOs that work in this area?

The Pharmaceutical Journal, June 18, 2015

Malini Guha 

In his laboratory at the Beth Israel Deaconess Medical Center in Boston, Massachusetts, Harvard professor Vikas Sukhatme has identified several surface markers found on a type of immune cell called a myeloid-derived suppressor cell (MDSC).

March 2015

Northwestern Mutual Wealth Management Advisor Steve Braun recently received a 2015 Community Service Award as the Most Exceptional Volunteer for his work with Cures Within Reach.  Learn about our Executive Board member, Steve Braun, and his efforts to support our growth.  Steve Braun's Community Involvement

 

 

Part II: Business Review

Drug Discovery World, Spring 2015

Dr. Stephen Naylor, David M. Kauppi and Judge M. Schonfeld

There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.The activity and productivity of DRPx focused companies as well as pharmaceutical company efforts appear to offer some encouragement in providing solutions to the myriad of problems the industry faces at the present time.These efforts can only be sustained and expanded if the dynamic variables of viable and creative business models are identified and understood. In this work we describe the lessons that can be learnt from surveying the landscape of the DRPx industry.This analysis includes both the successes and the failures of past DRPx companies.We introduce the various stakeholders that are shifting the decision process of DRPx implementation and acceptance away from the pharmaceutical industry. In addition the component pieces necessary to enhance the value of a DRPx company are discussed and the top 10 mini- blockbuster and blockbuster DRPx drugs are introduced. Finally, we assess and compare an assortment of DRPx business models and evaluate the current climate of the DRPx industry.

Read Full Article Here

MILWAUKEE, March 11, 2015 PRNewswire

Whether it's becoming a Big Brother, setting up a lemonade stand or advocating for economic and social equality for women and girls, Northwestern Mutual financial representatives are actively involved in their communities. To recognize this, Northwestern Mutual, through its foundation, is awarding financial representatives with the company's 2015 Community Service Award.

Three winners in each of the four regions will receive a $15,000 or $20,000 grant for their nonprofit, while an additional winner per region is named most exceptional, earning $25,000 for their organization. In total, the foundation is awarding $285,000 in grants.

"Each year I'm overwhelmed by the outstanding work our financial representatives are doing in their communities and their strong spirit of giving is echoed across our company each day," said John Kordsmeier, president, Northwestern Mutual Foundation. "The impact of these individuals extends our business and reaches the heart of what we do every day by putting others first."

Drug Discovery World

Dr. Stephen Naylor & Judge M. Schonfeld, Winter 2014

The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.

The growing interest, activity and productivity in Drug Repurposing, Drug Repositioning and Drug Rescue (DRPx) appears to offer some encouragement in finding solutions to the myriad of problems the pharmaceutical companies must overcome. Here we describe the current status of DRPx, discuss the emerging consensus on terminology and describe the tools, technologies and approaches utilised in DRPx. 

Read full article here

How We Get To Next 

Nick Sireau, September 29, 2014

NickSireauBruce Bloom is just one man, but he potentially knows a way to save millions of lives. Addressing a room full of pharma executives at a conference in Boston, he commands their full attention. He speaks with authority and passion.The topic is one that industry has shirked for too long. It’s about how to find new purposes for existing drugs when there’s no intellectual property left to protect. Most of us don’t realize that many of the drugs we rely upon regularly can be used for many different, often unrelated, illnesses...

                                            Read full article here 

DiscoverMagDiscover Magazine

Carolyn Graybeal, August 22, 2014

Each year in the U.S. millions of dollars' worth of useable medication is destroyed. While at the same time one in four working adults cannot afford their medication. It is a confusing and unnecessary contradiction.
Fortunately innovative organizations recognize that by recycling or repurposing medication it is possible to limit waste and conserve resources while helping individuals live healthier lives.

Full Article

June 18, 2014

New web portal, built in collaboration with GlobalCures, will accelerate the open medical research approach to discover affordable, effective repurposed therapies

Marquette Intellectual Property Review, Volume 18, Issue 1 (2014)

Dr. Bruce Bloom

The current medical solution industry, with amazing scientists and businesspeople working as hard as they can, is not creating treatments and cures for most of the world's diseases. Pharma in 2013 is using a fifty-year-old business model to leverage current knowledge and technology, but that is generating few new treatments, and each treatment increases healthcare costs.  Read More

 

Sign up for our eNewsletter today!

 

First Name




Cures Within Reach

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Monday the 23rd. Copyright 2018 Cures Within Reach.